
The FDA cleared Access MeMed BV, a host-response blood test that helps distinguish bacterial from viral infections in adults and children in as little as 15 minutes.
Weight loss for patients with NAFLD is the key to improvement of histopathologic features. Find out what else you know about treatment of NAFLD/NASH with 8 guidance-based questions.
The American Association for the Study of Liver Diseases (AASLD) outlines a data‐supported approach to the treatment nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH) in a guidance document published in
While disease-specific pharmacotherapy is still in clinical trials, there are a number of recommended approaches to management using existing medications and non-drug intervention. Find out what you know about these with the following 8 questions.






